During the past decade, Middlemore Clinical Trials conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 2 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Middlemore Clinical Trials" are "B-cell Chronic Lymphocytic Leukemia" (1 trials) and "Psoriatic Arthritis" (1 trials). Many other conditions were trialed in "Middlemore Clinical Trials" in a lesser frequency.

Most popular intervention types in "Middlemore Clinical Trials" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Apremilast 30 mg" (1 trials) and "Lenalidomide" (1 trials). Other intervention names were less common.

The vast majority of trials in "Middlemore Clinical Trials" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Middlemore Clinical Trials". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Middlemore Clinical Trials, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Middlemore Clinical Trials, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".